Quick Answer
Ernexa Therapeutics Inc. reported Revenue (ASC 606) of $5.80 million for fiscal year 2020.
Ernexa Therapeutics Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2020 | $5.80M | -70.7% |
| 2019 | $19.81M | -15.1% |
| 2018 | $23.34M | +9.7% |
| 2017 | $21.27M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2020 | $1.48M | -67.8% | +95.9% |
| June 30, 2020 | $754.0K | -85.6% | -68.5% |
| March 31, 2020 | $2.39M | -50.5% | -47.7% |
| September 30, 2019 | $4.58M | -23.7% | -12.4% |
| June 30, 2019 | $5.23M | -7.5% | +8.2% |
| March 31, 2019 | $4.83M | -16.1% | -19.5% |
| September 30, 2018 | $6.00M | +15.5% | +6.2% |
| June 30, 2018 | $5.65M | +1.8% | -1.9% |
- Ernexa Therapeutics Inc. showed a decrease of -70.7% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2017–2020 period, Ernexa Therapeutics Inc.’s revenue (asc 606) has declined by 72.7% (from $21.27 million to $5.80 million).
- The most recent figure is from Ernexa Therapeutics Inc.’s fiscal year 2020 report (Form 10-K), filed with the SEC on March 11, 2021.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: